Halozyme grants Intrexon exclusive, worldwide rights to use Halozyme's rHuPH20 recombinant human PH20 hyaluronidase enzyme drug delivery technology to develop a subcutaneous formulation

Halozyme Therapeutics Inc.

U.S. / Mid-Cap Biopharma ($1-$50 billion)

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Intrexon Corp.

U.S. / Mid-Cap Biopharma ($1-$50 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced